The rs6910071 variant sits within an intron of TSBP1 (testis-expressed basic protein 1, formerly C6orf10), a gene embedded in the major histocompatibility complex (MHC) on chromosome 6p21. The MHC is the most densely associated genetic region for rheumatoid arthritis (RA), driven principally by HLA-DRB1 alleles encoding a five-amino-acid sequence called the shared epitope¹¹ shared epitope
A conserved sequence in the third hypervariable region of the HLA-DRβ chain (positions 70–74) that shapes the peptide-binding groove and is the dominant genetic risk factor for seropositive RA. Because rs6910071 sits in strong linkage disequilibrium with HLA-DRB1*04 shared-epitope haplotypes, it functions as a reliable GWAS tag for this high-risk haplotype block — catching much of the MHC-mediated RA susceptibility in a single testable SNP.

The Mechanism

TSBP1 itself is broadly expressed at low levels throughout adult tissues, with highest expression in the testis and modest expression in immune-relevant tissues including blood and lymph nodes. The gene activates protein kinase A (PKA) signaling and interacts with at least 14 genes implicated in autoimmune pathways. However, the primary clinical signal at rs6910071 is almost certainly indirect: the G allele tags a chromosomal haplotype block that includes HLA-DRB1*04:01 and related shared-epitope alleles, which together shape antigen presentation by class II MHC molecules to CD4+ T cells.

Shared-epitope HLA-DRB1 alleles promote autoimmunity through two mechanisms. First, they preferentially present citrullinated peptides — peptides carrying arginine residues enzymatically converted by PAD enzymes — leading to the anti-citrullinated protein antibodies (ACPA/anti-CCP) that are the serological hallmark of seropositive RA. Five amino-acid positions within HLA-DRB1, HLA-B, and HLA-DPB1 explain most of the MHC-wide RA association²² Five amino-acid positions within HLA-DRB1, HLA-B, and HLA-DPB1 explain most of the MHC-wide RA association
Fine-mapping study by Raychaudhuri et al. 2012 using imputed HLA alleles across 5,539 RA cases and 20,169 controls. Second, epigenetic dysregulation in the region may amplify risk: whole-blood bisulfite sequencing in RA patients identified differential hypomethylation at C6ORF10 CpG sites³³ differential hypomethylation at C6ORF10 CpG sites
Pearson correlation between C6ORF10 methylation and anti-CCP/RF levels was significantly negative, p<0.05, and the degree of hypomethylation correlated with serological risk markers anti-CCP and rheumatoid factor.

The Evidence

rs6910071 has been independently replicated in multiple large datasets. The most rigorous demonstration comes from a phenome-wide association study (PheWAS) across 29,349 Europeans in two biorepositories (MyCode/Geisinger and BioVU/Vanderbilt), which identified rs6910071 as the top replicating signal for rheumatoid arthritis and inflammatory polyarthropathies (pMETAL = 2.58 × 10⁻⁹⁴⁴ pMETAL = 2.58 × 10⁻⁹
60 cases/2,964 controls in MyCode; 81 cases/2,818 controls in BioVU). A separate genomic phenotype study identified the same variant as a novel locus for polymyalgia rheumatica⁵⁵ polymyalgia rheumatica
OR = 1.5, 95% CI 1.3–1.6, P = 1.3 × 10⁻¹⁰ in 413 PMR cases vs. 5,782 controls, a closely related inflammatory condition also strongly associated with HLA-DRB1*04.

A network analysis of 116 pleiotropic RA-associated genes identified C6orf10 as a hub gene⁶⁶ identified C6orf10 as a hub gene
Shared across nine autoimmune diseases including RA, psoriasis, SLE, multiple sclerosis, Graves' disease, and type 1 diabetes, consistent with the broader role of the HLA region in determining autoimmune susceptibility across organ systems. The G allele is notably more common in Europeans (~20%) than in African (~6%) or East Asian (~8%) populations, mirroring the higher prevalence of seropositive RA in northern European populations.

Practical Actions

Carriers of the G allele — particularly GG homozygotes — carry a meaningfully elevated prior probability of developing seropositive RA. The most evidence-based response to this genetic signal is early serological surveillance. ACPA (anti-CCP) and rheumatoid factor (RF) testing can identify preclinical seropositive RA years before joint damage begins; positive serology in the context of a high-risk genetic profile warrants rheumatology referral even before arthritis is clinically apparent.

Smoking is the primary modifiable environmental amplifier of shared-epitope RA risk: citrullination of lung proteins by cigarette smoke creates the neoantigens that, in shared-epitope carriers, trigger ACPA production. GG carriers who smoke face a combined gene-environment risk substantially larger than either factor alone.

Interactions

rs6910071 does not act in isolation. The strongest compound risk in RA comes from combining MHC-region HLA-DRB1 risk alleles (tagged by rs6910071) with non-HLA variants including PTPN22 R620W ([rs2476601 | The strongest non-HLA RA risk allele, increasing T-cell activation threshold]) and smoking exposure. When rs6910071-G is combined with rs2476601-A (PTPN22 R620W), the combined risk for seropositive RA exceeds either allele alone — a well-documented epistatic interaction where both T-cell and antigen-presentation pathways are simultaneously dysregulated.

In 2008, a landmark genome-wide association study¹¹ landmark genome-wide association study
Romeo et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nature Genetics, 2008. The Dallas Heart Study examined hepatic fat content across 2,111 individuals of diverse ancestry using magnetic resonance spectroscopy discovered something remarkable: a single genetic variant in the PNPLA3 gene explained more variation in liver fat content than obesity, diabetes, or alcohol consumption combined. The I148M variant (rs738409) has since been validated as the strongest genetic risk factor for the entire spectrum of fatty liver disease, from simple steatosis to cirrhosis and hepatocellular carcinoma.

PNPLA3 (patatin-like phospholipase domain-containing protein 3) encodes a 481-amino acid protein also called adiponutrin. The protein localizes to the surface of lipid droplets²² lipid droplets
Lipid droplets are cellular organelles that store triglycerides and other neutral lipids. In hepatocytes, excessive lipid droplet accumulation manifests as fatty liver in liver cells and the endoplasmic reticulum, where it functions in triglyceride metabolism and lipid droplet remodeling.

The Mechanism

The I148M variant results from a C-to-G substitution at position 43,928,847 on chromosome 22, changing codon 148 from isoleucine (I) to methionine (M). This single amino acid substitution fundamentally alters how the protein behaves. The mutant 148M protein localizes more extensively to lipid droplets³³ localizes more extensively to lipid droplets
Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology, 2014 than the wild-type protein and exhibits markedly reduced triglyceride hydrolase activity.

Studies using radioactive tracers demonstrate that the I148M variant slows down triglyceride hydrolysis⁴⁴ slows down triglyceride hydrolysis
PNPLA3 is regulated by glucose in human hepatocytes, and its I148M mutant slows down triglyceride hydrolysis. American Journal of Physiology, 2012 during lipid depletion, essentially trapping fat in liver cells. The protein's normal function involves selectively remodeling triglycerides by incorporating and releasing specific fatty acids, but the 148M variant disrupts this delicate metabolic choreography. The result: hepatocytes accumulate lipid droplets they cannot efficiently clear, initiating a cascade that can progress from simple fat accumulation to inflammation, fibrosis, and cirrhosis.

The Evidence

The strength of association between I148M and liver disease is exceptional by genetic standards. In the original Dallas Heart Study⁵⁵ original Dallas Heart Study
Romeo et al., 2008, individuals homozygous for the 148M variant (GG genotype) had more than twice the hepatic fat content of non-carriers (CC genotype). This finding has been replicated across dozens of cohorts worldwide.

A 2011 meta-analysis⁶⁶ 2011 meta-analysis
Sookoian & Pirola. Meta-analysis of the influence of I148M variant of PNPLA3 on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology, 2011 of 16 studies covering 3,902 patients with biopsy-proven NAFLD found that GG homozygotes had 3.24-fold higher odds of advanced necroinflammatory scores and 3.2-fold higher odds of fibrosis compared to CC individuals. Effect sizes of this magnitude are rare in common genetic variants.

The risk extends beyond fatty liver itself. A 2014 meta-analysis of cirrhosis⁷⁷ 2014 meta-analysis of cirrhosis
Liu et al. The rs738409 variant of the PNPLA3 gene and cirrhosis: a meta-analysis. Journal of Lipid Research, 2014 including 2,023 patients demonstrated that each copy of the G allele increases cirrhosis risk by 86% (OR 1.86, 95% CI 1.64-2.12). GG homozygotes face a more than 3-fold increased risk (OR 3.41, 95% CI 2.77-4.18) compared to CC individuals.

Perhaps most concerning, the variant substantially increases risk of hepatocellular carcinoma⁸⁸ hepatocellular carcinoma
Liu et al. Association between the PNPLA3 variant and hepatocellular carcinoma: Evidence from a meta-analysis of individual participant data. Hepatology, 2013, particularly in the context of alcohol-related liver disease. Studies show GG homozygotes have approximately 4.4-fold increased HCC risk compared to non-carriers in populations with existing liver disease.

Practical Implications

The silver lining: while the I148M variant increases susceptibility to liver fat accumulation, it also appears to enhance response to intervention⁹⁹ enhance response to intervention
Genetic variation in PNPLA3 confers sensitivity to weight loss-induced decrease in liver fat in humans. American Journal of Gastroenterology, 2011. GG homozygotes achieve 2.5-fold greater reductions in liver fat with low-calorie, low-carbohydrate diets compared to CC individuals. This suggests that carriers who maintain healthy body weight and limit refined carbohydrates may substantially mitigate their genetic risk.

The variant shows particularly strong gene-diet interactions¹⁰¹⁰ gene-diet interactions
Santoro et al. Hepatic fat accumulation is modulated by the interaction between the rs738409 variant in PNPLA3 and dietary omega-6/omega-3 PUFA intake. PLOS One, 2012. In GG carriers, hepatic fat content correlates strongly with dietary carbohydrate and sugar intake, while dietary patterns favoring omega-3 over omega-6 polyunsaturated fatty acids appear protective. Hispanic children homozygous for the 148M variant show positive correlations between liver fat and total sugar intake that aren't seen in non-carriers.

Alcohol represents a critical modifiable risk factor. Even light alcohol consumption¹¹¹¹ light alcohol consumption
Stickel et al. PNPLA3 rs738409, environmental factors and liver-related mortality in the US population. Journal of Hepatology, 2024 significantly amplifies the genetic risk, while coffee consumption appears protective. A 2024 population study found that drinking three or more cups of coffee daily attenuated the increased risk of liver-related mortality in G-allele carriers.

For GG homozygotes with established liver disease, enhanced surveillance may be warranted. Current hepatology guidelines recommend ultrasound screening every six months¹²¹² ultrasound screening every six months
Liu et al. Carriage of the PNPLA3 rs738409 C>G polymorphism confers an increased risk of NAFLD-associated hepatocellular carcinoma. Journal of Hepatology, 2014 for cirrhotic patients to enable early HCC detection, and PNPLA3 genotype may help identify high-risk individuals who benefit most from this surveillance.

Interactions

PNPLA3 I148M interacts with several other genetic variants that influence NAFLD progression:

TM6SF2 rs58542926 (E167K): The TM6SF2 variant primarily affects hepatic fat accumulation through impaired VLDL secretion, while having minimal effect on fibrosis. Combined effects studies¹³¹³ Combined effects studies
Dongiovanni et al. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study. Journal of Lipid Research, 2017 show that individuals carrying both PNPLA3 148M and TM6SF2 167K variants have additive effects on steatosis severity. The combination confers higher liver fat content than either variant alone, though PNPLA3 remains the stronger predictor of fibrosis progression.

MBOAT7 rs641738: This variant in membrane-bound O-acyltransferase domain containing 7 associates specifically with fibrosis rather than steatosis. Individuals carrying both PNPLA3 148M and MBOAT7 risk alleles show compounded fibrosis risk¹⁴¹⁴ compounded fibrosis risk
Dongiovanni et al., 2017, suggesting these variants act on complementary pathways. MBOAT7 modulates phosphatidylinositol remodeling, while PNPLA3 affects triglyceride metabolism, but both ultimately promote hepatic inflammation and scarring.

HSD17B13 rs72613567: This splice variant produces a truncated protein and represents one of the few protective genetic factors¹⁵¹⁵ protective genetic factors
Abul-Husn et al. Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease. Hepatology International, 2021 for liver disease. HSD17B13 loss-of-function alleles reduce aminotransferases and lower risk of NASH, cirrhosis, and HCC. Critically, the protective effect of HSD17B13 variants appears to partially attenuate¹⁶¹⁶ partially attenuate
Abul-Husn et al., 2021 the increased risk conferred by PNPLA3 148M. Individuals carrying both the PNPLA3 GG genotype and HSD17B13 protective variants show intermediate disease severity compared to those with PNPLA3 GG alone.

GCKR rs780094: Variants in glucokinase regulator modestly increase liver fat through enhanced de novo lipogenesis. Epistatic analysis¹⁷¹⁷ Epistatic analysis
Méndez-Sánchez et al. Contribution of PNPLA3, GCKR, MBOAT7, NCAN, and TM6SF2 genetic variants to hepatocellular carcinoma development in Mexican patients. International Journal of Molecular Sciences, 2025 suggests a three-way interaction between PNPLA3, GCKR, and MBOAT7 that influences HCC risk, particularly in populations with high baseline NAFLD prevalence like Hispanics and Mexicans.

These gene-gene interactions explain why some individuals with PNPLA3 148M develop aggressive liver disease while others remain relatively protected. Polygenic risk scores incorporating 4-5 common variants including PNPLA3, TM6SF2, MBOAT7, and HSD17B13 show improved prediction of cirrhosis and HCC risk compared to PNPLA3 alone and may help refine clinical risk stratification.

The reduced folate carrier (RFC1, encoded by SLC19A1) is the principal route by which folates and antifolate drugs — including methotrexate — enter most human cells. Like any well-studied transporter gene, SLC19A1 carries a cluster of common variants that tend to travel together in haplotype blocks. rs12659 (Pro232Pro; 6318C>T on the coding strand) is one of four variants that define the second linkage disequilibrium block of SLC19A1, the others being rs1051266, rs1131596, and rs3788200.

The Mechanism

rs12659 itself is a synonymous variant¹¹ synonymous variant
A synonymous variant changes the DNA sequence but not the amino acid — the codon changes from one proline codon to another at position 232. Because the amino acid is unchanged, the variant does not directly alter transporter structure or function. Its clinical relevance comes primarily from its role as a haplotype tag: the A allele (plus-strand notation, corresponding to the coding-strand T allele) tags a specific version of the SLC19A1 gene that co-occurs with other functional variants in the same block, most prominently the transport-reducing rs1051266 T allele. This is why rs12659 signals in studies even though it encodes no protein change.

Synonymous variants can theoretically affect mRNA stability, splicing efficiency, or translation speed through codon-usage effects, and this possibility has been raised for SLC19A1 rs12659. However, direct experimental evidence for such a mechanism at this specific position is currently lacking.

The Evidence

Individual-SNP analysis in a pilot study of 100 Chinese rheumatoid arthritis patients receiving methotrexate found that rs12659 G allele carriers had significantly better clinical response: Cen et al. 2022²² Cen et al. 2022
Cen H et al. Associations Between Genetic Polymorphisms Within Transporter Genes and Clinical Response to Methotrexate in Chinese Rheumatoid Arthritis Patients. Pharmacogenomics Pers Med, 2022 reported RR=1.42 (95% CI=1.02–1.97, P=0.04) for EULAR good/moderate response under a dominant model (G/G + A/G vs A/A). Haplotype analysis in the same study showed the TGAA haplotype (carrying the A allele at rs12659 together with the rs1051266-T transport-reducing allele) was associated with worse MTX response (OR=0.37, 95% CI=0.14–0.98), indicating the haplotype effect is primarily driven by rs1051266.

In a separate study of 122 lung cancer cases vs 122 matched controls in Xuan Wei, China — a population with exceptionally high lung cancer rates attributed to indoor coal smoke — Shen et al. 2005³³ Shen et al. 2005
Shen M et al. Polymorphisms in folate metabolic genes and lung cancer risk in Xuan Wei, China. Lung Cancer, 2005 found the Pro232Pro C allele (plus-strand G allele) associated with increased lung cancer risk (OR=1.83, 95% CI=1.02–3.28). This finding requires caution: the sample was small, the population was exposed to an unusually potent carcinogen, and the result has not been replicated in non-coal-smoke contexts.

A PharmGKB pharmacogenomics summary⁴⁴ PharmGKB pharmacogenomics summary
Gong L et al. SLC19A1 Pharmacogenomics Summary. Pharmacogenet Genomics, 2010 notes that the Pro232Pro variant did not show a significant association with non-Hodgkin lymphoma across 1,000+ cases and controls, and showed a positive association with cervical carcinoma platinum-based chemotherapy response in one study, suggesting tissue- and drug-specific effects.

Practical Actions

Because rs12659 is a synonymous haplotype tag rather than a functional variant, it does not independently indicate any specific dietary or supplementation change. Its primary clinical value is as a marker that travels with the folate transport-modifying rs1051266 allele. Individuals homozygous for the A allele at rs12659 are very likely to also carry the rs1051266 T allele, meaning the folate transport considerations for that variant apply — principally, preferring methylfolate (5-MTHF) over synthetic folic acid and ensuring adequate cellular folate intake.

For patients taking methotrexate for rheumatoid arthritis, inflammatory bowel disease, or oncological indications, rs12659 A-allele homozygosity — as part of the TGAA haplotype context — may signal a need for closer monitoring of clinical response and folate status, since the linked rs1051266-T allele reduces cellular uptake of both folate and methotrexate.

Interactions

rs12659 is in strong linkage disequilibrium with rs1051266 (the functionally characterized G80A/His27Arg variant already profiled separately), rs1131596 (5'-UTR), and rs3788200 (intronic). In the four-SNP TGAA haplotype block, the dominant signal appears driven by rs1051266 — the transporter's known functional variant. Because this platform already profiles rs1051266 directly, rs12659 adds independent information only when an individual carries a discordant haplotype (rs12659-A without rs1051266-T, or vice versa), which is rare given the high LD between them.

Pathway-level interactions with MTHFR rs1801133 and MTHFD1 rs2236225 operate at the level of rs1051266's transport function, not rs12659 per se.

Deep inside your cells, lysosomes serve as the recycling centres responsible for breaking down worn-out proteins, lipids, and cellular debris. One enzyme is central to this process in neurons: glucocerebrosidase (GCase)¹¹ glucocerebrosidase (GCase)
encoded by the GBA1 gene, GCase converts glucosylceramide into glucose and ceramide — a routine lysosomal step whose impairment has outsized consequences for brain health. GBA variants are already established as the strongest known genetic risk factor for Parkinson's disease, and rs12752133 represents an independent intronic signal at the same locus with a large, replicated effect on the earliest detectable stage of this disease spectrum: REM sleep behavior disorder (RBD).

RBD — in which people physically act out vivid dreams during REM sleep — is not merely a sleep disorder. It is now recognised as a prodromal synucleinopathy marker, typically preceding Parkinson's disease diagnosis by a decade or more. Identifying your genetic risk profile at the GBA locus while still in this pre-motor window is the most actionable time to intervene.

The Mechanism

rs12752133 is an intronic variant located 94 nucleotides downstream of exon 11 in GBA1, at chromosomal position chr1:155,235,587 (GRCh38). The GBA gene is transcribed from the minus strand, so the plus-strand C→T change corresponds to a G→A transition on the coding strand within intron 11. The precise molecular mechanism by which this intronic position modulates disease risk is not yet fully characterized, but the leading hypothesis is that it alters pre-mRNA splicing efficiency or GBA1 expression levels, either independently or by influencing the regulatory architecture of the broader GBA1-GBAP1 locus region.

The downstream consequence is the same as for other GBA risk variants: reduced glucocerebrosidase activity impairs the autophagy-lysosomal pathway that dopaminergic neurons depend on to degrade misfolded proteins. When GCase activity falls, the glycolipid glucosylceramide accumulates. Glucosylceramide directly stabilises alpha-synuclein oligomers — the toxic species that seed Lewy body formation — while simultaneously inhibiting GCase further, creating a self-reinforcing vicious cycle²² self-reinforcing vicious cycle
Moors et al. Mov Disord 2016: lysosomal dysfunction and alpha-synuclein aggregation in post-mortem GBA-PD brain tissue between lysosomal failure and protein aggregation.

Importantly, rs12752133 and the N409S coding variant (rs76763715) are independent signals at the GBA locus — they sit 256 bp apart, likely in different functional elements of the gene, and their risk contributions are statistically separable in GWAS analysis.

The Evidence

The clearest evidence for rs12752133 comes from the largest genome-wide association study of REM sleep behavior disorder conducted to date³³ the largest genome-wide association study of REM sleep behavior disorder conducted to date
Krohn et al. Genome-wide association study of REM sleep behavior disorder identifies polygenic risk and brain expression effects. Nature Communications, 2022. This meta-analysis enrolled 2,843 RBD cases and 139,636 controls, identifying five genome-wide significant loci: SNCA, GBA, TMEM175, INPP5F, and SCARB2. At the GBA locus, rs12752133-T reached p=5×10⁻¹⁴ with an odds ratio of 2.09 (95% CI 1.73–2.54) — a very large effect size for a GWAS finding. The GBA and TMEM175 loci were notable for being shared across all three main synucleinopathies studied: isolated RBD, Parkinson's disease with probable RBD, and Parkinson's disease without RBD, suggesting a fundamental biological role in the synucleinopathy continuum.

The broader case for GBA as the most consequential Parkinson's disease risk gene was established by the landmark multicenter NEJM study⁴⁴ the landmark multicenter NEJM study
Sidransky et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. NEJM, 2009, which analyzed 5,691 PD patients and 4,898 controls across 16 international centers and found an overall OR of 5.43 for any GBA mutation. The Nalls et al. 2019 meta-analysis⁵⁵ The Nalls et al. 2019 meta-analysis
Nalls et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease. Lancet Neurology, 2019 — spanning 37,688 cases and 1.4 million controls — confirmed GBA as one of 78 replicated genomic regions, underscoring the locus's biological centrality to PD pathogenesis.

Practical Actions

For T-allele carriers, the GBA mechanism suggests three actionable priorities: supporting lysosomal function and GCase activity, monitoring for prodromal RBD before motor symptoms appear, and avoiding environmental neurotoxins that compound dopaminergic vulnerability. The ambroxol pharmacological chaperone approach — currently in Phase 2 clinical trials targeting GBA-related neurodegeneration — represents the most mechanistically direct intervention available. Ambroxol binds misfolded GCase in the endoplasmic reticulum, stabilising its conformation to increase lysosomal delivery and enzyme activity; preclinical and open-label human data confirm it increases GCase activity and reduces CSF alpha-synuclein levels in GBA variant carriers.

Interactions

rs12752133 and the coding N409S variant (rs76763715) are independent signals at the GBA locus. Carriers of both may face compound impairment of GCase expression (via the intronic regulatory effect of rs12752133-T) and GCase protein folding (via the missense effect of N409S), potentially compounding lysosomal failure beyond either variant alone. This is a compound action candidate.

Within the broader synucleinopathy picture, GBA risk alleles interact with SNCA variants (rs356219, rs356182, rs2736990) — elevated alpha-synuclein from SNCA and impaired lysosomal clearance from GBA represent two independent drivers of Lewy body pathology converging on the same dopaminergic neuron population. The TMEM175 lysosomal potassium channel variant (rs76904798) is another locus identified in the same RBD GWAS that impairs lysosomal acidification — a second lysosomal mechanism compound action candidate alongside GBA.

The chromosome 17q21 locus is the most robustly replicated genetic risk region for childhood-onset asthma, identified in the landmark Moffatt et al. 2007 GWAS¹¹ Moffatt et al. 2007 GWAS
994 asthma cases vs 1,243 controls; 17q21 SNPs reached p<10⁻¹²; ORMDL3 expression was the strongest correlate across all genes at the locus in Nature. Among the constellation of correlated variants in this locus, rs12936231 stands out as the most powerful eQTL²² eQTL
expression quantitative trait locus — a variant that changes how much of a nearby gene is produced, rather than changing the protein itself for ORMDL3 in circulating blood cells. It sits within an intron of ZPBP2, in the heart of a ~130-kb regulatory haploblock spanning IKZF3, ZPBP2, GSDMB, ORMDL3, LRRC3C, and GSDMA.

ORMDL3 encodes an endoplasmic reticulum transmembrane protein that is a master regulator of sphingolipid synthesis³³ sphingolipid synthesis
ORMDL3 inhibits serine palmitoyltransferase, the rate-limiting enzyme in de novo ceramide/sphingolipid biosynthesis, linking ER homeostasis to airway inflammation. When ORMDL3 is overexpressed, ER stress accumulates, NF-κB and STAT3 pathways activate, and airway epithelial cells release pro-inflammatory cytokines that drive asthma exacerbations and allergic wheeze.

The Mechanism

rs12936231 lies within a critical regulatory hub. The C and G alleles differ in how they position nucleosomes and recruit CTCF⁴⁴ CTCF
CTCF is a chromatin insulator protein that controls 3D genome folding; its binding site preferences can switch at SNP positions, reshaping which enhancers talk to which promoters. The asthma-risk (C) allele and the nearby rs4065275 together switch the CTCF occupancy pattern at the ZPBP2 region, creating distinct long-range promoter-enhancer loops that are absent in G-allele carriers. The functional consequence: CD4+ T cells from risk-allele carriers show approximately 3-fold higher ORMDL3 expression⁵⁵ approximately 3-fold higher ORMDL3 expression
Schmiedel et al. 2016 — ORMDL3 mRNA levels were ~3-fold elevated in activated CD4+ T cells from risk haplotype carriers vs. non-risk carriers.

Elevated ORMDL3 inversely suppresses IL-2 production in activated memory T cells: when ORMDL3 was knocked down experimentally, IL-2 increased significantly, demonstrating that the risk haplotype dampens one arm of adaptive immunity (IL-2-driven T cell expansion) while amplifying innate airway inflammation.

The most precise quantification of rs12936231's regulatory role came from an eQTL fine-mapping study in African American children⁶⁶ eQTL fine-mapping study in African American children
Ober et al. 2020 Lancet Resp Med, n=85 PBMC donors; rs12936231 showed β=1.19 [1.12-1.24] for ORMDL3 and β=1.24 [1.15-1.32] for GSDMB, p<0.0001 for both, confirming it as the top eQTL across the locus in blood cells.

The Evidence

The connection between rs12936231 genotype and childhood asthma risk is multi-layered. The strongest clinical evidence comes from the vitamin D × 17q21 interaction studies⁷⁷ vitamin D × 17q21 interaction studies
Kelly et al. ERJ 2019 (VDAART cohort) and Knihtilä et al. ERJ 2021 (VDAART + COPSAC2010): GG children whose mothers received prenatal vitamin D3 had 51% lower asthma/wheeze risk (HR 0.49, p=0.032); CC children showed no benefit (HR 1.08, p=0.751), which established a pharmacogenomic interaction: vitamin D3 supplementation works partly by upregulating sphingolipid synthesis enzymes that ORMDL3 normally suppresses. In CC individuals, constitutively elevated ORMDL3 blocks this pathway, abolishing the protective effect.

A 2021 maternal cohort study replicated this finding across two independent trials (VDAART HR 0.54, p<0.001; COPSAC2010 HR 0.56, p=0.021⁸⁸ VDAART HR 0.54, p<0.001; COPSAC2010 HR 0.56, p=0.021
Knihtilä et al. ERJ 2021 — maternal GG/GC genotype predicted offspring vitamin D response in both North American and Danish cohorts), identifying the maternal genotype — not just the child's — as the key modulator.

Allele-specific chromatin remodeling at ZPBP2/GSDMB/ORMDL3⁹⁹ Allele-specific chromatin remodeling at ZPBP2/GSDMB/ORMDL3
Verlaan et al. AJHG 2009 — allele-specific nucleosome positioning and promoter activity identified at rs12936231; haplotype association p=1.78×10⁻⁸ established the functional basis for why rs12936231 has independent regulatory significance beyond simply being in LD with other 17q21 SNPs.

Practical Actions

The clinical implication for C-allele carriers centers on airway inflammation management and the vitamin D–sphingolipid axis. Because elevated ORMDL3 blunts the anti-inflammatory effects of vitamin D on airway epithelium, CC individuals require higher circulating 25(OH)D levels to achieve the same sphingolipid-normalization effect that GG individuals get at standard supplementation levels. Maintaining 25(OH)D above 40–50 ng/mL (100–125 nmol/L) — rather than the standard "sufficient" threshold of 20 ng/mL — is supported by the mechanistic data in this pathway.

The interaction with smoking documented in UK adults suggests the C-allele effect on airway inflammation is amplified by tobacco smoke exposure, making avoidance of smoke exposure particularly important for C-allele carriers with asthma or allergic airway disease.

Interactions

rs12936231 is in strong but incomplete LD with other 17q21 variants. The CTCF-switching effect requires rs12936231 and rs4065275 acting together. The independent GWAS-significant asthma signal carried by rs2305480 (GSDMB missense p.Pro311Ser) and rs8076131 are in the same haploblock but can be partly separated statistically, meaning carriers of rs12936231 CC who also carry rs2305480 GG have an additive airway risk via two distinct mechanisms (regulatory ORMDL3 overexpression plus increased GSDMB pyroptotic activity). The IKZF3 variant rs2872507 at the same locus has a distinct pleiotropic profile — GG is asthma-risk but AA is autoimmune-risk — creating complex genotype combinations worth tracking in multi-condition risk assessments.

The SLC30A8 gene encodes zinc transporter 8¹¹ zinc transporter 8
ZnT8 is a transmembrane protein that pumps zinc ions from the cytoplasm into insulin secretory granules inside pancreatic beta cells (ZnT8), a protein found almost exclusively in the insulin-producing beta cells of the pancreas. Its job is simple but critical: load zinc into the granules where insulin is stored. Zinc is essential for insulin to crystallize into its stable hexameric form — without adequate zinc, insulin is less stable, harder to store, and released less efficiently.

The rs13266634 variant changes a single amino acid at position 325 from arginine (encoded by the common C allele) to tryptophan (encoded by the T allele). This was one of the first type 2 diabetes risk loci identified by genome-wide association²² genome-wide association
Sladek R et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature, 2007, and it carries an unusual twist: the common allele (C, found in ~70% of people globally) is the risk allele, while the less common T allele is protective.

The Mechanism

ZnT8 sits in the membrane of insulin secretory granules and actively pumps zinc ions³³ zinc ions
Each insulin hexamer contains two Zn2+ ions at its core; roughly 70% of beta cell zinc resides in these granules into these compartments. Inside the granule, two zinc ions bind six insulin molecules to form a crystalline hexamer — the storage form of insulin. This crystallization increases storage capacity and protects insulin from premature degradation.

The Arg325 (C allele) and Trp325 (T allele) forms of ZnT8 differ in their zinc transport efficiency. Counterintuitively, the Arg325 version associated with the common C risk allele appears to transport zinc at higher capacity, yet carriers show impaired insulin processing⁴⁴ impaired insulin processing
Including elevated proinsulin-to-insulin ratios, suggesting that excess zinc granule loading may paradoxically interfere with the conversion of proinsulin to mature insulin and reduced first-phase insulin release. The Trp325 variant (T allele) has reduced transport activity but is associated with better insulin secretion dynamics.

This paradox was dramatically underscored when Flannick and colleagues⁵⁵ Flannick and colleagues
Flannick J et al. Loss-of-function mutations in SLC30A8 protect against type 2 diabetes. Nat Genet, 2014 discovered that rare complete loss-of-function mutations in SLC30A8 confer a striking 65% reduction in type 2 diabetes risk. This inverted the prevailing assumption that more ZnT8 activity equals better insulin function, and established ZnT8 inhibition as a potential therapeutic target.

The Evidence

The original GWAS⁶⁶ original GWAS
Sladek R et al. Nature, 2007 identified rs13266634 in a French cohort, and replication was swift. A meta-analysis of 46 studies⁷⁷ meta-analysis of 46 studies
Fan M et al. Association of SLC30A8 gene polymorphism with type 2 diabetes, evidence from 46 studies. Endocrine, 2016 encompassing 71,890 cases and 96,753 controls confirmed the association across European, Asian, and African populations with an odds ratio of approximately 1.15 per C allele (CC vs TT: OR ~1.53).

The EUGENE2 study⁸⁸ EUGENE2 study
Staiger H et al. The common SLC30A8 Arg325Trp variant is associated with reduced first-phase insulin release. Diabetologia, 2008 showed that CC homozygotes had a 19% decrease in first-phase insulin release during intravenous glucose tolerance testing compared to T allele carriers, providing a functional mechanism linking genotype to diabetes risk.

Critically, the relationship between this variant and diabetes risk is modifiable by zinc status. Chu and colleagues⁹⁹ Chu and colleagues
Chu A et al. Interactions between zinc transporter-8 gene and plasma zinc concentrations for impaired glucose regulation and type 2 diabetes. Diabetes, 2014 found that each 10 ug/dL increase in plasma zinc was associated with 22% lower odds of type 2 diabetes in TT carriers, 17% lower in CT carriers, but only 7% lower in CC carriers — a significant gene-nutrient interaction.

A zinc supplementation trial¹⁰¹⁰ zinc supplementation trial
Maruthur NM et al. Effect of zinc supplementation on insulin secretion: interaction between zinc and SLC30A8 genotype in Old Order Amish. Diabetologia, 2015 in 55 non-diabetic Amish individuals found that after 14 days of zinc supplementation (50 mg elemental zinc twice daily), carriers of the T allele experienced a 26% increase in early insulin response to glucose at 5 minutes compared to CC homozygotes — the first direct evidence that zinc supplementation can differentially improve beta cell function based on SLC30A8 genotype.

Practical Implications

This SNP sits at the intersection of genetics and nutrition. The key insight is that zinc status matters more for some genotypes than others. CC homozygotes have the highest baseline diabetes risk but show the smallest benefit from zinc optimization, while T allele carriers — who already have lower risk — get the most benefit from adequate zinc intake.

For everyone, ensuring adequate zinc intake supports insulin function. Good dietary sources include oysters, red meat, poultry, beans, nuts, and pumpkin seeds. For CC homozygotes, the focus should extend beyond zinc to broader metabolic health: maintaining a healthy weight, regular physical activity, and monitoring blood glucose are important given the modestly elevated diabetes risk.

Interactions

SLC30A8 rs13266634 interacts with other type 2 diabetes risk loci. The combination of the CC genotype here with TCF7L2 rs7903146 risk alleles (TT or CT) compounds overall diabetes risk through independent but converging pathways — SLC30A8 affecting insulin storage and release, TCF7L2 affecting beta cell development and incretin signaling. Individuals carrying risk alleles at both loci should be especially vigilant about metabolic health monitoring.

The SLC30A8 variant also influences ZnT8 autoantibody specificity in type 1 diabetes. The Arg325 (C allele) form is the dominant autoantibody target. While this does not change the type 2 diabetes risk interpretation, it adds a layer of immunological significance to this variant.

Adiponectin is the body's most abundant adipokine — a hormone secreted almost exclusively by adipose tissue¹¹ hormone secreted almost exclusively by adipose tissue
it activates AMPK in muscle and liver, suppresses hepatic glucose output, and reduces vascular inflammation that acts as a master regulator of insulin sensitivity, lipid metabolism, and metabolic inflammation. Low circulating adiponectin is one of the most consistent biomarkers of metabolic dysfunction, predicting insulin resistance, type 2 diabetes, NAFLD, and cardiovascular disease independently of BMI. The ADIPOQ gene on chromosome 3 encodes this protein, and variation across the locus — particularly in two linkage disequilibrium blocks spanning the promoter and intron 1 — accounts for a meaningful portion of inter-individual differences in circulating adiponectin.

rs16861205 (chr3:186,843,845 GRCh38) sits in intron 1 of ADIPOQ, within the same linkage disequilibrium block as the promoter variant rs266729. Because rs16861205 and rs266729 are in LD, some of their phenotypic associations overlap — but studies that genotyped both simultaneously demonstrate that rs16861205 has independent contributions to adiponectin dynamics and body weight regulation.

The Mechanism

Intronic variants in ADIPOQ intron 1 may influence gene expression via several mechanisms: disruption of intronic regulatory elements²² regulatory elements
sequences within introns that bind transcription factors or modulate chromatin accessibility, altered pre-mRNA splicing kinetics, or tagging of functional variants in the local LD block. rs16861205 (G>A) is an intron variant catalogued in dbSNP Build 157 with no direct protein-coding consequence. Its functional role is thought to be regulatory — either through direct intronic regulatory activity or as a haplotype tag for the broader LD block 1, which contains the promoter.

The haplotype block containing rs16861205 and rs266729 spans the region approximately −14,811 to −4,120 base pairs relative to the ADIPOQ transcription start, covering the proximal promoter and intron 1. Variants in this block collectively influence ADIPOQ transcriptional activity and circulating adiponectin levels. Because rs16861205 participates in this block, its A allele may tag a local chromatin state that alters adiponectin expression — and the gender-specific effects observed in African American cohorts suggest the regulatory influence may be modulated by sex hormone signalling on ADIPOQ transcription.

The Evidence

The most informative data come from two independent cohorts. In the Finnish Diabetes Prevention Study³³ Finnish Diabetes Prevention Study
n=507 overweight subjects with impaired glucose tolerance randomised to intensive lifestyle intervention vs control; Siitonen et al. 2011, rs16861205 was significantly associated with baseline body weight (GG carriers: 87.7 kg vs. GA/AA carriers: 84.3 kg, dominant model p=0.006) and with 4-year longitudinal weight change (additive p=0.028, dominant p=0.008). Strikingly, the A allele was associated with a greater increase in serum adiponectin concentrations over 4 years (additive p=0.040, dominant p=0.014), particularly among participants who lost weight during the first year of intervention. This suggests the A allele may reflect a distinct regulatory state in which adiponectin production is more responsive to weight loss.

A contrasting pattern was observed in the Jackson Heart Study⁴⁴ Jackson Heart Study
n=2,968 African American adults (1,131 men, 1,837 women); Davis et al. 2015 — the largest population-specific analysis of rs16861205 to date. In women, the A allele was significantly associated with lower circulating adiponectin in the fully adjusted model (beta=−0.13, SE=0.05, p=0.003). No significant association was found in men (beta=−0.11, SE=0.061, p=0.074). A gender-stratified haplotype analysis Yansane et al. 2015⁵⁵ Yansane et al. 2015 confirmed that rs16861205 participates in a haplotype block (with rs6444174, rs1403697, and rs7641507) that shows significant effects on adiponectin in women but not men.

Taken together, the evidence points to rs16861205 as a variant that modulates adiponectin levels in a sex-specific and context-dependent way. The A allele appears to reduce baseline adiponectin in women (particularly African American women) while potentially conferring greater adiponectin responsiveness to weight loss intervention.

Practical Actions

For carriers of the A allele — particularly women — the primary concern is ensuring circulating adiponectin remains within the protective range (>8 µg/mL in women,

6 µg/mL in men). The most evidence-based dietary intervention for raising adiponectin is omega-3 fatty acids: a meta-analysis of 43 randomised trials with 3,434 participants found that EPA and DHA supplementation significantly increases adiponectin, with the largest effects in individuals with low baseline levels. Replacing dietary saturated fat with monounsaturated and polyunsaturated fats activates PPARgamma in adipocytes, stimulating ADIPOQ transcription regardless of intronic genotype.

For AA homozygotes and AG women with metabolic risk factors, measuring serum adiponectin directly provides the most actionable information — it reveals whether the regulatory variant is actually suppressing output to clinically meaningful levels, and it allows monitoring of dietary intervention response over time.

Interactions

rs16861205 is in the same LD block as rs266729, the well-characterised ADIPOQ promoter variant on the platform. The combined haplotype effect of LD block 1 (rs266729 + rs16861205) on adiponectin is likely stronger than either SNP alone, but the direction of the interaction requires haplotype-level analysis. Users carrying the rs266729 G risk allele alongside the rs16861205 A allele may have the most pronounced reduction in adiponectin signalling from this LD block.

rs182052 (ADIPOQ −10066G>A), also in the platform, shows a diet-genotype interaction with monounsaturated fat intake: rs182052 G/G homozygotes increase adiponectin on a high-MUFA diet while A-allele carriers do not — making fat quality a particularly relevant modifiable factor for the broader ADIPOQ LD block.

The FADS2 gene on chromosome 11 encodes delta-6 desaturase¹¹ delta-6 desaturase
The rate-limiting enzyme that performs the first desaturation step converting dietary short-chain fatty acids (plant-based ALA and LA) into longer, biologically active forms including EPA, DHA, and arachidonic acid, the enzyme that opens the gateway to all long-chain polyunsaturated fatty acid synthesis from plant precursors. rs174616 is an intronic FADS2 variant that tags a distinct linkage disequilibrium block within the FADS1/FADS2 cluster. Carriers of the A allele produce less delta-6 desaturase activity — the enzyme that catalyzes the first rate-limiting step in both omega-3 (ALA → EPA → DHA) and omega-6 (LA → arachidonic acid) synthesis.

The Mechanism

rs174616 lies within intron 7 of the FADS2 gene at chromosome 11 position 61,861,650 (GRCh38). Like other intronic variants across the FADS cluster, it acts through a regulatory rather than coding mechanism — influencing FADS2 expression levels, and in at least one study, through associated DNA methylation changes at a CpG site (cg07999042) in the FADS2 promoter region.

The A allele reduces delta-6 desaturase output, creating a characteristic substrate-accumulation, product-deficit pattern: the precursor linoleic acid (LA) and alpha-linolenic acid (ALA) build up, while the downstream products — gamma-linolenic acid (GLA)²² gamma-linolenic acid (GLA)
First omega-6 product after FADS2 acts on linoleic acid; further elongated to DGLA then arachidonic acid, dihomo-gamma-linolenic acid (DGLA)³³ dihomo-gamma-linolenic acid (DGLA)
Omega-6 intermediate between GLA and arachidonic acid; anti-inflammatory precursor to series-1 prostaglandins, arachidonic acid (ARA), EPA, and DHA — are reduced. Because this is the first rate-limiting enzyme in the pathway, impairment ripples downstream to affect all long-chain PUFA products.

The Evidence

The foundational study for the FADS cluster is Schaeffer et al. 2006⁴⁴ Schaeffer et al. 2006
Schaeffer L et al. Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids. Human Molecular Genetics, 2006, which genotyped 18 FADS1/FADS2 cluster SNPs including rs174616 in 727 German adults, demonstrating strong associations between FADS haplotypes and serum phospholipid fatty acid composition. The rs174616 A allele tagged a haplotype block independently associated with the substrate-accumulation, product-deficit PUFA signature.

Zec et al. 2020⁵⁵ Zec et al. 2020
Zec MM et al. FADS2 polymorphisms are associated with plasma arachidonic acid and estimated desaturase-5 activity in a cross-sectional study. Nutrition Research, 2020 found that the A allele was associated with lower plasma arachidonic acid and reduced estimated delta-5 desaturase activity, and identified a significant gene-diet interaction in which dietary carbohydrate percentage modified the effect on Δ6 desaturase activity.

In a case-control study of Han Chinese individuals⁶⁶ case-control study of Han Chinese individuals
Yao et al. Polymorphisms of rs174616 in the FADS1-FADS2 gene cluster is associated with a reduced risk of type 2 diabetes mellitus in northern Han Chinese people. Diabetes Res Clin Pract, 2015 (618 cases, 618 controls), the A allele was associated with a decreased conversion rate of LA to arachidonic acid (AA/LA ratio) and a modestly reduced risk of type 2 diabetes, suggesting that lower arachidonic acid production — and the resulting reduction in pro-inflammatory eicosanoids — confers some metabolic benefit in high-carbohydrate dietary contexts.

A selection genetics analysis by Romero-Hidalgo et al. 2024⁷⁷ Romero-Hidalgo et al. 2024
Romero-Hidalgo S et al. Selection scan in Native Americans of Mexico identifies FADS2 rs174616: Evidence of gene-diet interactions affecting lipid levels and Delta-6-desaturase activity. Heliyon, 2024 found that rs174616 is the most highly differentiated FADS2 SNP across global populations, with the A allele approaching fixation (94%) in Native Americans of Mexico, occurring at ~47% in Europeans and only ~19% in East Asians. This extreme population differentiation and evidence of positive selection suggest the A allele conferred a metabolic advantage in populations subsisting on high-carbohydrate, low-marine-fat diets — contexts where lower arachidonic acid production may reduce inflammatory tone.

Walle et al. 2019⁸⁸ Walle et al. 2019
Walle P et al. Liver DNA methylation of FADS2 associates with FADS2 genotype. Clinical Epigenetics, 2019 identified a mechanistic link: the rs174616 genotype was significantly associated with DNA methylation at the FADS2 CpG site cg07999042 in liver tissue, with A allele carriers showing distinct methylation patterns, providing a plausible epigenetic mechanism for how this intronic variant regulates enzyme expression.

Practical Actions

The core implication of A allele carriage is consistent with the broader FADS2 picture: dietary plant-based omega-3 (from flax, chia, walnuts) supplies ALA that requires FADS2 to begin converting toward EPA and DHA. With reduced FADS2 activity, this first conversion step is rate-limited and less EPA/DHA reaches circulation, regardless of ALA intake. Preformed EPA and DHA from fatty fish, fish oil, or algae-based supplements bypass this bottleneck entirely.

The omega-6 side matters too: reduced arachidonic acid production from dietary LA changes the balance of eicosanoid production, favoring less inflammatory signaling. Limiting excess omega-6 from refined seed oils (soybean, corn, sunflower) reduces the LA load on an already constrained FADS2 enzyme, supporting a better omega-3:omega-6 balance even when EPA/DHA are in short supply.

For vegetarians and vegans, the implications are particularly pronounced: without marine food sources, the only pathway to adequate EPA/DHA is through algae-based supplements that provide these fatty acids in preformed bioavailable form.

Interactions

rs174616 is in linkage disequilibrium with other FADS2 variants (rs174575, rs1535) and with the FADS1 delta-5 desaturase variants (rs174547, rs174537). The FADS cluster forms two linked haplotype blocks: carriers of risk alleles at rs174616 often also carry risk alleles at other cluster variants, compounding the PUFA synthesis deficit. When both FADS2 (delta-6) and FADS1 (delta-5) variants are present, the upstream deficit from FADS2 reduces substrate available for FADS1, compounding the reduction in EPA and arachidonic acid. Any APOE or cardiovascular risk variants that increase inflammatory sensitivity make adequate omega-3 status even more critical.

CYP2C9 is the primary enzyme responsible for metabolizing warfarin (Coumadin), one of the most widely prescribed and dangerous medications in clinical practice. Warfarin has an extremely narrow therapeutic window¹¹ Narrow therapeutic window: small difference between effective dose and toxic dose - too little and you risk blood clots, too much and you risk life-threatening bleeding. CYP2C9 genotype is one of the key determinants of the right dose for each individual.

The Mechanism

The CYP2C9*2 variant²² rs1799853 causes an arginine-to-cysteine substitution at position 144³³ Amino acid change: arginine to cysteine at position 144 (R144C). This amino acid change reduces the enzyme's catalytic efficiency to about 50% of normal. The enzyme is produced in normal quantities but works at roughly half speed, leading to slower clearance of warfarin and other CYP2C9 substrates. The *2 allele is most common in European populations (about 13%) and essentially absent in East Asian populations.

Warfarin Dosing Impact

Warfarin dosing is one of the most successful applications of pharmacogenomics in clinical practice. The FDA-approved warfarin label includes pharmacogenomic dosing tables based on CYP2C9 and VKORC1 genotypes. Patients with CYP2C9*2 typically need lower warfarin doses to achieve therapeutic INR levels, and they take longer to reach a stable dose. Two landmark randomized trials -- the EU-PACT trial⁴⁴ EU-PACT trial
Pirmohamed M et al. A Randomized Trial of Genotype-Guided Dosing of Warfarin. N Engl J Med, 2013 and the COAG trial⁵⁵ COAG trial
Kimmel SE et al. A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing. N Engl J Med, 2013 -- tested genotype-guided dosing in clinical practice.

Beyond Warfarin

CYP2C9 also metabolizes phenytoin (seizure medication), NSAIDs (ibuprofen, celecoxib), and several diabetes medications (glipizide, tolbutamide). Poor metabolizers may experience increased side effects from these drugs at standard doses. For NSAIDs, the CPIC guideline⁶⁶ CPIC guideline
Theken KN et al. CPIC guideline for CYP2C9 and NSAID therapy. Clin Pharmacol Ther, 2020 recommends reduced doses or alternative agents for poor metabolizers due to increased risk of gastrointestinal bleeding.

Practical Implications

If you carry the *2 allele, this is important information for any future warfarin therapy. Pharmacogenomic-guided warfarin dosing has been shown to reduce the time to stable therapeutic dosing and decrease the risk of bleeding complications. Several online dosing calculators (like warfarindosing.org⁷⁷ warfarindosing.org
Pharmacogenomic warfarin dosing calculator) incorporate CYP2C9 genotype alongside clinical factors.

AGER encodes RAGE (Receptor for Advanced Glycation End-Products), a pattern recognition receptor¹¹ pattern recognition receptor
A cell-surface protein in the immunoglobulin superfamily that detects advanced glycation end-products, HMGB1, S100 proteins, and amyloid-beta — triggering NF-κB-mediated inflammatory gene expression found on endothelial cells, neurons, smooth muscle, immune cells, and alveolar epithelium. Unlike the Gly82Ser missense variant (rs2070600), which alters receptor structure, the −374T/A polymorphism acts upstream — it sits in the AGER promoter and directly controls how much RAGE protein is made.

The variant is catalogued on the GRCh38 plus strand with reference allele A and alternate allele T at chr6:32184610. Because AGER is transcribed from the minus strand, published papers use coding-strand notation: the common coding-strand T allele corresponds to plus-strand A, while the functional coding-strand A allele (the one studied as the promoter-active variant) corresponds to plus-strand T. The T allele on the plus strand is the allele that increases RAGE expression.

The Mechanism

In 2001, Hudson et al.²² Hudson et al.
Hudson BI et al. Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. Diabetes, 2001 used chloramphenicol acetyltransferase (CAT) reporter assays to demonstrate that the −374A coding allele (plus-strand T) increases RAGE promoter-driven transcription approximately threefold compared to the −374T coding allele (P<0.001). The mechanism involves differential binding of nuclear protein extracts from both monocyte- and hepatocyte-derived cell lines, indicating that a transcription factor or co-activator binds preferentially to the A-containing promoter sequence.

Increased RAGE transcription elevates both forms of RAGE: full-length membrane-bound RAGE and soluble RAGE (sRAGE)³³ soluble RAGE (sRAGE)
The secreted truncated form of RAGE that acts as a decoy receptor — capturing circulating AGEs and HMGB1 before they reach cell-surface RAGE, thereby damping inflammatory activation. This dual elevation creates a complex phenotype: more sRAGE circulates as a protective decoy, but more membrane-bound RAGE also sits on cell surfaces ready to fire when AGEs break through the sRAGE buffer. Under low AGE conditions, the sRAGE increase may dominate (hence the protective cardiovascular associations in non-diabetic cohorts). Under chronic hyperglycemia, where AGE loads are overwhelming, the elevated membrane RAGE amplifies inflammation more than the extra sRAGE can neutralize.

The Evidence

Transcriptional activity. The fundamental functional finding — that the −374A coding allele tripled RAGE promoter activity — was established by Hudson et al. (2001)⁴⁴ Hudson et al. (2001) and provides the mechanistic rationale for all subsequent clinical associations. This is a bona fide functional variant, not a tagging SNP.

Diabetic microvascular complications. The most replicated clinical associations involve diabetic nephropathy and retinopathy. Lindholm et al. (2006)⁵⁵ Lindholm et al. (2006)
Lindholm E et al. The −374 T/A polymorphism in the gene encoding RAGE is associated with diabetic nephropathy and retinopathy in type 1 diabetic patients. Diabetologia, 2006 studied 867 type 1 and 2,467 type 2 diabetic patients in Scandinavian cohorts and found that carrying the A/T or A/A coding genotypes (i.e., at least one T on the plus strand) associated with diabetic nephropathy (p=0.006) and sight-threatening retinopathy (p=0.03) in type 1 diabetes. A meta-analysis by Tao et al. (2017)⁶⁶ Tao et al. (2017)
Tao D et al. Association between the RAGE −374T/A gene polymorphism and diabetic retinopathy in T2DM. Rev Assoc Med Bras, 2017 combining 9 case-control studies (1,705 DR cases, 2,236 controls) found that the −374A coding allele (T on the plus strand) conferred OR=1.22 (95% CI 1.05–1.41) in the dominant model and OR=1.26 (95% CI 1.07–1.47) in the heterozygote model for diabetic retinopathy, with risk present in both Asian and Caucasian subgroups. Abdel-Azeez et al. (2009)⁷⁷ Abdel-Azeez et al. (2009)
Abdel-Azeez HA et al. Association of the RAGE −374 T/A gene polymorphism and circulating soluble RAGE with nephropathy in type 1 diabetic patients. Egypt J Immunol, 2009 found OR=2.36 (95% CI 1.1–5.6) for the −374A coding allele (T plus strand) predicting diabetic nephropathy (n=70), with sRAGE levels paradoxically elevated in nephropathy patients — a marker of inflammatory burden rather than protection at that stage of disease.

Cardiovascular disease. In non-diabetic contexts, findings diverge. Falcone et al. (2004)⁸⁸ Falcone et al. (2004)
Falcone C et al. Relationship between the −374T/A RAGE gene polymorphism and angiographic coronary artery disease. Int J Mol Med, 2004 showed in 259 non-diabetic Italians that the −374AA coding genotype (plus-strand TT) was independently protective against angiographically confirmed CAD (OR=0.33, 95% CI 0.15–0.73, p=0.006) — found in 22.6% of controls but only 9.7% of CAD patients. This likely reflects the sRAGE-elevating effect of higher RAGE transcription in a non-AGE-overloaded context. Conversely, Aslan et al. (2024)⁹⁹ Aslan et al. (2024)
Aslan EI et al. Receptor for advanced glycation end products polymorphisms in coronary artery ectasia. Gene, 2024 found that the −374A coding allele (T plus strand) was independently associated with coronary artery ectasia¹⁰¹⁰ coronary artery ectasia
Abnormal dilation of coronary arteries — a distinct clinical entity from obstructive CAD, associated with impaired endothelial function and platelet activation (p<0.001, AUC=0.713 for discrimination), suggesting that in certain vascular phenotypes the elevated RAGE expression drives pathological remodeling.

Type 1 diabetes with poor metabolic control. Pettersson-Fernholm et al. (2003)¹¹¹¹ Pettersson-Fernholm et al. (2003)
Pettersson-Fernholm K et al. The functional −374 T/A RAGE gene polymorphism is associated with proteinuria and cardiovascular disease in type 1 diabetic patients. Diabetes, 2003 found in 996 Finnish T1D patients with HbA1c >9.5% that the −374AA coding genotype (TT on plus strand) was paradoxically protective: 30% had normal albumin excretion vs 10% in TT+TA coding carriers (p=0.01), and rates of CHD (6% vs 14%) and MI (2% vs 14%) were markedly lower. In this extreme glycemic environment, the highest sRAGE producers (TT plus strand) may maintain enough decoy activity to partially offset the AGE burden.

A note on the evidence paradox. The literature on −374T/A contains genuine heterogeneity: the same functional allele appears protective in non-diabetic cardiovascular studies and in poorly controlled T1D, yet harmful in diabetic retinopathy meta-analyses. The likely explanation is that sRAGE and membrane RAGE co-scale with RAGE expression, and their net effect depends critically on the ambient AGE load. The evidence level for this SNP is rated moderate, not strong, because of these context-dependent inconsistencies. Single-genotype actions focus on the best-replicated risk associations (diabetic microvascular complications), where multiple cohorts and a meta-analysis converge.

Practical Actions

The actionable consequence of carrying the T plus-strand allele (−374A coding) depends on metabolic context. For users with normal glucose metabolism, the clinical significance of this SNP alone is modest; the main priority is protecting against future hyperglycemia, which would convert the elevated RAGE expression from a complex mixed signal into a clear-cut driver of microvascular damage. For anyone with prediabetes or diabetes, this variant is a strong reason to pursue tight glycemic control and regular screening for early microvascular complications (retina, kidney).

Dietary advanced glycation end-products — formed by high-heat cooking and abundant in processed foods — add to endogenous AGE production and further activate RAGE-signaling. Reducing dietary AGE intake through cooking method changes (moist heat over dry high-heat) is the most directly mechanism-specific intervention available for RAGE pathway variants.

Interactions

rs1800624 is frequently co-analyzed with rs2070600 (Gly82Ser) as part of an AGER haplotype. Peng et al. (2022)¹²¹² Peng et al. (2022)
Peng Y et al. Genetically modified circulating levels of AGEs and their soluble receptor with risk and mortality of breast cancer. Cancers, 2022 showed that rs2070600 and rs1800624 together dose-dependently predict sRAGE levels, and specific haplotype combinations interact with high AGE exposure to confer breast cancer risk. Users carrying both the rs2070600 T allele (reduced sRAGE shedding) and rs1800624 T allele (elevated total RAGE expression) may experience compounding effects on the AGE-RAGE axis — elevated RAGE surface density with impaired sRAGE buffering simultaneously. This combination warrants a compound action covering both variants (see interaction_candidates below).